Safety and clinical performance of the magnesium-based bioresorbable coronary stent (Freesolve) in the treatment of patients with lesions in the coronary arteries: BIOMAG-II
Résumé de l'étude
The objective of the study is to evaluate the safety and efficacy of the bioresorbable Freesolve stent from BIOTRONIK in the treatment of patients with up to two stenoses of the coronary arteries, compared to the Abbott Xience stent, which is made of a permanent material. This is an international, multicenter clinical trial to compare the Freesolve stent with the Xience stent regarding the target lesion failure (TLF) rate at 12 months. TLF is a composite rate of cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR) rate. Patients will be randomly implanted either with the bioresorbable Freesolve stent (intervention group) or with the permanent Xience stent (control group) and will be followed up to 5 years after the intervention.
(BASEC)
Intervention étudiée
The common name for the intervention is percutaneous transluminal coronary angioplasty (PTCA). During this procedure under local anesthesia, a catheter will be placed inside the groin or arm to access an artery. A bioresorbable Freesolve stent or a Xience stent will be implanted in the coronary artery requiring treatment. The correct positioning is monitored by angiography, and a balloon is inflated to open the prosthesis and press it against the vessel wall. Then, the deflated balloon is removed from the vessel, and the prosthesis remains in place. The procedure for implanting the bioresorbable Freesolve stent is the same as for the Xience stent. Depending on the usual treatment process of the study physician, the entire procedure will last between 30 and 60 minutes.
(BASEC)
Maladie en cours d'investigation
Stenosis of the coronary arteries (heart blood vessels)
(BASEC)
- The subject is eligible for the percutaneous transluminal coronary angioplasty (PTCA) intervention. - The subject is an acceptable candidate for aortocoronary bypass surgery. - The subject is eligible for dual antiplatelet therapy (DAPT). (BASEC)
Critères d'exclusion
- The subject presents clinical symptoms and/or electrocardiogram (ECG) changes compatible with a "STEMI" myocardial infarction within 72 hours prior to the study procedure. - The subject has undergone PTCA in the target vessel within the last 12 months prior to the study procedure, or PTCA in another vessel within 72 hours prior to the study procedure. - The subject is on dialysis or has renal insufficiency. (BASEC)
Lieu de l’étude
Bâle, Berne, Fribourg, Genève, Lugano, Zurich
(BASEC)
Sponsor
BIOTRONIK AG
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Dimitra Antonopoulou
+41 75 429 5753
dimitra.antonopoulou@clutterbiotronik.comBIOTRONIK AG
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Genève
(BASEC)
Date d'approbation du comité d'éthique
07.05.2024
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
BIOMAG-II (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible